Tablets & Capsules

TC0718

Issue link: https://www.e-digitaleditions.com/i/1000772

Contents of this Issue

Navigation

Page 7 of 59

6 July 2018 Tablets & Capsules research Instrument detects formulation crystallinity WEST LAFAYETTE, IN—Resear- chers at Purdue University have developed an instrument based on tri- boluminescence that can detect if a drug formulation has a trace crystal- linity, which could negatively impact the drug's stability and bioavailability. The electro-mechanical device uses a solenoid to crush pharmaceutical powder on a microscope slide, emit- ting light that is directly proportional to the formulation's crystallinity but invisible to the naked eye. A photo multiplier tube beneath the slide then measures the light emitted. The instrument provides rapid screening of amorphous solid dispersions and can detect crystallinity levels as low as 140 parts per million. Researchers hope to use the device to perform similar crystallinity testing in slurries. Single-tablet HIV treatment may be more effective than multi-tablet regimens HOUSTON, TX—Patients pre- scribed a once-daily single-tablet HIV treatment had better retention in care (initiating and maintaining antiretroviral therapy) and virologic suppression compared to patients taking a once-daily multi-tablet treat- ment, according to research pub- lished in the February issue of AIDS Care journal. The study followed 1,026 patients beginning HIV treat- ment, with 622 receiving a once- daily single-tablet regimen and 406 receiving a once-daily multi-tablet treatment. After one year, the results showed that patients on the sin- gle-tablet treatment achieved more than 80 percent retention in care and 84.4 percent virologic suppression compared to 72.7 retention and 77.6 percent suppression for patients receiving the multi-tablet regimen. markets Favorable regulatory environment to boost continuous manufacturing DALLAS, TX—The global con- tinuous manufacturing market will grow at a compound annual rate greater than 12 percent through 2025, according to a report by Orbis Research. Market growth can be attributed to the cost-effectiveness and efficiency of continuous pharma- ceutical manufacturing as well as the favorable regulatory environment. The report identifies Thermo Fisher Scientific, GEA, Hosokawa Micron, Coperion, Glatt, Korsch, Munson Machinery, and L.B. Bohle as key players in this market. Tablet segment expected to drive desiccant market growth BOSTON, MA—The global phar- maceutical desiccant market is fore- cast to grow 4.39 percent annually through 2025 due to a growing aging population, various government ini- tiatives to ensure drug quality, and the expanding pharmaceutical mar- ket. Of the types of desiccants used, silica gel holds the largest market galenIQ ™ – the bulk filler-binder. Great choice. Great taste. • galenIQ™ is pharma-grade Isomalt (Ph. Eur., USP-NF, BP, JP) that makes medicine taste pleasant. • The filler-binder with sweet sugar-like taste. • Due to its multifunctionality your best choice excipient to be used for a broad variety of dosage forms. Our team of experts is available for your product development with galenIQ ™ . Please contact us: info@galenIQ.com · www.galenIQ.com

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC0718